
The first batches of the Sputnik V anti -icing vaccine will enter all regions of Russia by September 14, Interfax reports .
The publication is given by the statement of the head of the Russian Ministry of Health Mikhail Murashko.
“ The first small parties are already shipped. They are shipped to all regions, the Leningrad region will also receive among the first. Now, in fact, the first samples of the vaccine will already be delivered until Monday , ”said Murashko.
The head of the Ministry of Health noted that the department plans to monitor the health status of the vaccinated through a mobile application - all data will be assembled to the special system.
Context:
On August 11, Russian President Vladimir Putin announced that the Hamalea Center registered the world's first vaccine from coronavirus - “satellite V”. At the time of registration of the vaccine, only two stages of the study passed, and the third was going to spend later. Because of this, fears appeared in the scientific community that such a haste could be at the risk of end consumers, but the Russian authorities reject this probability.
On August 27, it became known that in September Russia will have another vaccine. The State Scientific Center for Virology and Biotechnology "Vector" in Novosibirsk is operating on it. The developers of the second drug received more time for testing.
Now the Sputnik V vaccine is undergoing post -stroke trials, in which 40 thousand people will take part. At the same time, a quarter of them will receive a placebo instead of a real drug. Post -storage tests will last from two to six months.
Earlier in the center of N.F. Gamalei, they planned to obtain permission to issue a batch of vaccines into civil circulation from September 10 to 13. At the same time, at the end of August, the head of the Ministry of Health, Mikhail Murashko, said that in the framework of the third stage of testing, the vaccine began to be supplied to medical institutions of Moscow.
What does it mean:
The Russian Sputnik V vaccine in the West is criticized in particular for the lack of an important stage of mass testing. However, the drug will still be used - at least in the Russian Federation.